Cardano's public Dijkstra testnet currently runs Conway protocol version 11 on node release 11.1.3. The network plans to upgrade to Dijkstra version 12 following a prerelease of node 11.2 and a hard-fork initiation, though no date is set yet. Node 11.2 is an early test milestone that does not include the Leios scaling upgrade, which is being tested separately on the Musashi testnet. These developments mark important steps toward Cardano's planned network scaling improvements.
Cardano's public Dijkstra testnet update comes as the broader cryptocurrency market shows mixed momentum. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 25, 2026 23:01 WIB: out of 50 major cryptocurrencies, 35 rose and 14 fell today. Notable movers include LUNC (Terra Classic) with a price of Rp0,816 and a 92% buy order activity, BCH (Bitcoin Cash) priced at Rp4.959.745 with 61% sell order activity, and COTI at Rp187 with 92% buy order activity.
Justin Sun, founder of TRON, announced plans to include tokenized U.S. Treasuries in addition to tokenized equities on the TRON network. This marks an expansion of the network's tokenized asset offerings, which had previously focused mainly on stocks...
On October 25, Ethena surged 8.66% to $0.203, leading gains among the top 90 cryptocurrencies excluding stablecoins. A total of 69 assets showed positive movement, with Rain up 7.35%, Dash rising 6.29%, Zcash climbing 5.78%, and Quant increasing 5.58...
Rocket Lab's stock has fallen nearly 30% in a month following a delay in the Neutron rocket launch due to a defect in its carbon-composite tank. Despite this, the company's backlog surged 137% year over year to $2.36 billion, driven by defense contra...
Risk assets including Bitcoin and Ethereum fell over the weekend due to geopolitical tensions and rising oil prices, causing increased market volatility and a significant deleveraging of altcoin positions by about $9 billion. Despite the selloff, thi...
Oruka Therapeutics will announce Week 16 results for ORKA-001 from its EVERLAST-B Phase 2b trial targeting moderate-to-severe plaque psoriasis on October 26, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the dat...
